{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:58:19Z","timestamp":1791021499334,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HORIZON-MISS-CANCER-2022-01"],"award-info":[{"award-number":["HORIZON-MISS-CANCER-2022-01"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejca.2025.115790","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:29:11Z","timestamp":1757770151000},"page":"115790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Convergence of science, regulations and society in cancer clinical research: A perspective based on the EORTC DE-ESCALATE Study"],"prefix":"10.1016","volume":"229","author":[{"given":"Denis","family":"Lacombe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kromar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-8408","authenticated-orcid":false,"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115790_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, Castration-Sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2025.115790_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2025.115790_bib3","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (Peace-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115790_bib4","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, Double-Blind, phase III Titan study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115790_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard First-Line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2025.115790_bib6","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic Hormone-Sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115790_bib7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, Hormone-Sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2025.115790_bib8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.115790_bib9","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/pros.24777","article-title":"Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer","volume":"84","author":"Swami","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.ejca.2025.115790_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25826","article-title":"Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors","volume":"3","author":"Myint","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2025.115790_bib11","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/17425255.2021.1970745","article-title":"Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis","volume":"17","author":"Rizzo","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ejca.2025.115790_bib12","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jamaoncol.2023.0998","article-title":"Association of Second-generation antiandrogens with cognitive and functional toxic effects in randomized clinical trials","volume":"9","author":"Nowakowska","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.115790_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2025.43.5_suppl.20","article-title":"Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)","volume":"43","author":"Fisher","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115790_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 advanced prostate cancer consensus conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.115790_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1391825","article-title":"EORTC 2238 \u201cDe-Escalate\u201d: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors","volume":"14","author":"Grisay","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115790_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115076","article-title":"Do regulations and policies undermine the social value of independent academic research?","volume":"213","author":"Lacombe","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115790_bib17","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S1470-2045(24)00756-3","article-title":"Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the european organisation for research and treatment of cancer","volume":"26","author":"Cardoso Borges","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115790_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.2026","article-title":"Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe","volume":"7","author":"Vokinger","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.115790_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077391","article-title":"Added benefit and revenues of oncology drugs approved by the european medicines agency between 1995 and 2020: retrospective cohort study","volume":"384","author":"Brinkhuis","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2025.115790_bib20","doi-asserted-by":"crossref","first-page":"S623","DOI":"10.1016\/j.jval.2024.10.3131","article-title":"SA50 systematic literature review on economic evaluations and health economic models in the field of metastatic Castration-Sensitive prostate cancer","volume":"27","author":"Nguyen","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.ejca.2025.115790_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2019.03.014","article-title":"Establishing treatment optimisation as part of personalised Medicine development","volume":"113","author":"Lacombe","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115790_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2021.04.012","article-title":"Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: the experience of the european organisation for research and treatment of cancer","volume":"151","author":"Saesen","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115790_bib23","unstructured":"European Parliament and Council, Regulation (EU) No. 536\/2014 of 16 April 2014 on clinical trials on medicinal products for human use, 2014.(Accessed February 26, 2025).\u3008https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:02014R0536-20221205\u3009."},{"key":"10.1016\/j.ejca.2025.115790_bib24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.eururo.2009.02.016","article-title":"Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the south european uroncological group","volume":"55","author":"Calais da Silva","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.115790_bib25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2025.115790_bib26","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2025.115790_bib27","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1200\/JCO.2012.46.5492","article-title":"Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials","volume":"31","author":"Niraula","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115790_bib28","unstructured":"European Parliament and Council, Directive 2001\/20\/EC relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, 2001."},{"key":"10.1016\/j.ejca.2025.115790_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/17407745241309293","article-title":"Experiences with low-intervention clinical trials\u2014the new category under the european union clinical trials regulation","author":"de Jong","year":"2025","journal-title":"Clin Trials"},{"key":"10.1016\/j.ejca.2025.115790_bib30","unstructured":"European Commission, Accelerating Clinical Trials in the EU, (n.d. ).(Accessed April 1)2025\u3008https:\/\/accelerating-clinical-trials.europa.eu\/index_en\u3009."},{"key":"10.1016\/j.ejca.2025.115790_bib31","unstructured":"European Commission, The COMBINE programme, (n.d.)(Accessed August 14, 2025)\u3008https:\/\/health.ec.europa.eu\/medical-devices-topics-interest\/combine-programme_en\u3009."},{"key":"10.1016\/j.ejca.2025.115790_bib32","unstructured":".European Parliament and Council, Regulation (EU) 2017\/746 of 5 april 2017 on in vitro diagnostic medical devices, 2014(accessed March 24, 2025).\u3008https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32017R0746\u3009."},{"key":"10.1016\/j.ejca.2025.115790_bib33","unstructured":"European Parliament and Council, Regulation (EU) 2017\/745 of 5 april 2017 on medical devices, 2017."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:24:06Z","timestamp":1773123846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925005763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S0959804925005763"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115790","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convergence of science, regulations and society in cancer clinical research: A perspective based on the EORTC DE-ESCALATE Study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115790"}}